Aspen Believes It ‘Ticks All The Boxes’ As It Begins Submitting GLP-1 Dossiers
‘Our IP Is Good – But Now We Have Confidence In Submissions,’ Aspen Says
South Africa’s Aspen Pharma has discussed the “significant progress” it believes it has made in GLP-1s, with an eye on rolling-out semaglutide in non-US and non-EU markets beginning as early as 2026.
